Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2022-03-17 00:00:00 ET · period of report 2022-03-15 · accession 0000899243-22-011386 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-17 | 2022-03-15 | BBIO | Ellis Andrea | Dir | P - Purchase | $8.39 | +12.0K | 12.0K | New | +$100.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-15 | P | A | 12,000 | $8.39 | 12,000 | D | — | — | (F1) Represents the weighted average purchase price of the shares purchased from $8.38 to $8.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions as reported in this footnote. |